Besides antibody derived biopharmaceuticals there also a group of other aminoacid based compounds with interesting therapeutical capabilities: peptide therapeutics
Peptides represent a unique class of pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically distinct from both. As intrinsic signaling molecules for many physiological functions, peptides present an opportunity for therapeutic intervention that closely mimics natural pathways. Indeed, several peptide drugs are essentially “replacement therapies” that add back or supplement peptide hormones in cases where endogenous levels are inadequate or absent. This is exemplified by the isolation and first therapeutic use of insulin in the 1920s in diabetics who did not produce sufficient quantities of the hormone.
Protagen Protein Services (PPS) has excellent technical knowledge and long-standing experience in the detailed characterization of peptides and peptide therapeutic products such as:
Insulin, Factor VIII, G-CSF, EPO
With the significant advancements in biologics and biopharmaceutical over the years, peptides and proteins have emerged as a major new class of therapeutics with a host of new applications in the diagnostic as well as the therapeutic sector
PPS provides a strategic approach for characterizing biopharmaceutical products. Analysis is performed in a GMP compliant laboratory using validated techniques to satisfy the latest regulatory requirements.
Proteins as therapeutics have drawn a lot of scientific attention because they are part of many receptors and channels in the membranes, which facilitate transport of molecules within the body. Despite their involvement in various biochemical reactions, proteins also elicit high specificity with the molecular target. On the other hand, peptides have also been used widely as therapeutics in cancer, diabetes, infectious diseases and many other disorders that have long been studied for a solution. An advantage of peptides over other drugs is that they are highly versatile, providing a wide variety of pharmaceutical targets, high specificity and efficacious and, and show low toxicity levels at the same time, relatively safe and well tolerated. A total 60 peptide-based drugs are already in the market and several other therapeutic peptides are currently being evaluated in different phases of clinical trials
Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.
Protagen Protein Services (PPS) has extensive experience in analysis of different fusion proteins and can successfully support you with:
- Developability assessment of candidates
- Detailed Structural Characterization
- Development, Qualification up to Validation of specific analytical methods
- Stability Testing
- Release Testing
PPS is continously developing new methods for peptide therapeutics and is offering services for peptide therapeutics analysis like:
- Purity and integrity analysis by CE-SDS and cIEF analysis
- Identification by peptide mapping mass spectrometry
- Assessment of quantity by amino acid analysis and liquid chromatography (HIC, RP-HPLC, IEX)
- Aggregation analysis by SEC-MALLS and Analytical Ultracentrifugation (AUC)
- Glycosylation analysis by mass spectrometry, HILIC-FL and HPAEC-PAD
- Mass spectrometric assessment of free thiol groups and disulfide bridges
- Determination of molar extinction coefficient
- Specific functional and potency assays on request